Please login to the form below

Not currently logged in
Email:
Password:

Melinta names chief medical officer

Sue Cammarata has experience at Shire and Novartis
Meltina Sue Cammarata

Dr Sue Cammarata has joined Melinta Therapeutics as chief medical officer as the company advances the progress of its late-stage pipeline.

In her new role, Dr Cammarata will lead the company's global development and registration strategy, including the plan for lead product candidate delafloxacin, in phase III for skin infections.

She has prior experience in developing anti-infectives, including Cubicin (daptomycin) during her time at Novartis, where she served as VP and global programme head for the company's immunology and infectious disease franchises from 2008 to 2010.

Dr Cammarata spent seven years at Novartis in total, having joined the company from Pharmacia in 2003. At Pharmacia, she worked on the anti-infective Zyvox (linezolid).

Her most recent role prior to joining Melinta was as VP, clinical research at Shire's human genetic therapies division.

Melinta's CEO Mary Szela said: "The extensive expertise Sue gained while developing and commercialising Cubicin and Zyvox, two billion-dollar anti-infective products that are among the most widely prescribed, will be invaluable as we move our earlier stage antimicrobial candidates into and through the clinic." 

26th November 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics